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the 5-year DFS rate was 74%. Both JCOG0205 [14] and ACTS-
CC [2] in which oxaliplatin was not used and D3 lymph node
dissection was a standard surgery showed similar or better DFS
than that with oxaliplatin in the Western pivotal studies [3–5].
Prolonged peripheral neuropathy and high medical cost are
clinically and socially signiﬁcant problems in oxaliplatin-based
adjuvant chemotherapy. We have believed that if radical surgery
with sufﬁcient lymph node dissection and anatomically optimal
mesocolic excision is carried out, less-toxic and less-expensive
oral FUs without oxaliplatin could obtain comparable treatment
outcome to oxaliplatin-containing regimens.
However, there is the poor prognostic subgroup in stage III.
ACTS-CC02 trial which is a phase III study investigating beneﬁt
of adding oxaliplatin to FU under D3 dissection surgery for N2
colon cancer patients is in progress [15].
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A novel germline mutation of
PDGFR-bmight be associated
with clinical response of
colorectal cancer to regorafenib
We report an extraordinary response to regorafenib in a patient
with metastatic adenocarcinoma of the rectum. In order to iden-
tify the molecular target of this response, we analyzed 409
cancer genes by next-generation sequencing (NGS) of the
genomic DNA (patient tumor and blood) and discovered a
germline mutation of the platelet-derived growth factor receptor
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β (PDGFR-β) gene, a target of regorafenib. The patient (male,
Caucasian) was diagnosed with rectal cancer at the age of 37
years; the initial stage was pT3pN0cM0. The patient underwent
initially a rectal resection and adjuvant chemotherapy. Seven
years later, recurrence of disease with metastases was diagnosed.
Molecular analysis of the tumor demonstrated a KRAS wild-type
genotype. The patient underwent multiple systemic treatments
over 5 years. At this time, the patient became symptomatic with
pain and cough due to bone and lung metastases (Figure 1A).
Treatment with regorafenib was initiated. After 8 weeks, a posi-
tron emission tomography/computed tomography scan showed
a partial morphological and metabolic response (Figure 1B)
according to RECIST criteria. After 9 months from beginning of
this therapy, the patient is still in partial remission with
A B C
Figure 1. Positron emission tomography/computed tomography scans at baseline (A), after 8 weeks of treatment (B), after 5 months of treatment (C).
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Figure 2. Sanger sequencing of platelet-derived growth factor receptor β (PDGFR-β). (A) To verify the variant in PDGFR-β which was detected by next-
generation sequencing (NGS) in the responder to regorafenib, the same DNA derived from tumor tissue as used for NGS was ampliﬁed for the region of interest
and sequenced by Sanger sequencing. The variant p.A6V was successfully veriﬁed. (B) To investigate whether the veriﬁed mutation in PDGFR-β is tumor spe-
ciﬁc, DNA was isolated from peripheral blood mononuclear cells (PBMCs) (blood) from the responder to regorafenib and sequenced by Sanger sequencing.
The variant p.A6V was detected in PBMCs as well and thus deﬁned as germline mutation. (C) To analyze whether the germline mutation p.A6V in PDGFR-β
may be a private mutation in the responder to regorafenib, tumor samples of four additional colon carcinoma patients which did not respond to regorafenib
treatment were sequenced for the speciﬁc mutation in PDGFR-β. None of the nonresponders to regorafenib exhibited the mutation p.A6V.
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signiﬁcant improvement of the symptoms (Figure 1C).
Regorafenib inhibits the angiogenic and stromal receptor tyro-
sine kinases, vascular endothelial growth factors receptors, tyro-
sine kinase endothelial 2 and PDGFR-β. In colorectal cancer
patients, objective responses to regorafenib have been rarely
observed (1% response rate [1]). As our patient showed a re-
sponse lasting over 9 months, we analyzed the patient’s tumor
by NGS using targeted ampliﬁcation with the AmpliSeq [2]
Comprehensive Cancer panel (Ion Torrent, Life Technologies)
which includes all exons of 409 cancer genes; the ampliﬁed
regions were sequenced according to [3]. Alignment, variant
calling and ﬁltering were done with Ion Reporter v4.0 (Life
Technologies) and are summarized in supplementary Tables S1
and S2, available at Annals of Oncology online. We detected a
nonsynonymous point mutation of PDGFR-β at codon 6 (p.
A6V) which was conﬁrmed by Sanger sequencing (Figure 2A).
This mutation has already been described in the COSMIC data-
base (ID = 1435169) as a unique case out of 367 colon carcin-
omas investigated. As this represents a rare mutation, we
sequenced this region in the genomic DNA derived from the
patient’s peripheral blood mononuclear cells and detected the
same strong heterozygous signal, demonstrating this to be a
germline mutation (Figure 2B). Moreover, we could exclude the
presence of this mutation in the genomic DNA derived from
tumor samples of four patients affected by metastatic colorectal
cancer not responding to regorafenib (Figure 2C). A strong and
homogenous expression of PDGFR-β could be detected in the
patient’s tumor compared with the nonresponder patients (sup-
plementary Figure S1, available at Annals of Oncology online).
PDGF and their receptors (PDGFR-α, PDGFR-β and PDGFR-
αβ) play a critical role in cancer development [4, 5]. Mutations
involving up-regulation of PDGF and/or PDGFR have been
documented in a number of solid tumors and hematological
malignancies. In colon cancer, previous reports have shown sen-
sitivity of a cell line with mutation (p.T681I) of PDGFR-β, to
sorafenib [6] and a recent case report described another germ-
line mutation in exon 19 of PDGFR-β [7] associated with
increased pathway activation and survival. To date, mutations of
PDGFR-β have not been correlated to response to regorafenib,
neither in cell lines nor in patients. Here we describe for the ﬁrst
time the germline mutation c.17C>T (NM_002609.3) of
PDGFR-β, a target of regorafenib and hypothesize that this mu-
tation, in the signal peptide of PDGFR-β, might have an onco-
genic driver potential [8]. Although objective responders to
regorafenib are rare, it would be of major interest to conﬁrm this
result in a larger group of patients to deﬁne if PDGFR-β is a pre-
dictive marker to this treatment.
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Pharmacokinetic interaction
involving fenoﬁbrate and
everolimus
We have read with great attention the recent review by Aapro
et al. [1] on the management of adverse events in cancer patients
receiving everolimus. Although we agree with the authors that
high levels of triglycerids increase the risk of pancreatitis, we
question the opportunity of using ﬁbrates in this setting, in view
of the following observation.
A 57-year-old patient with a past history of hypertension and
smoking (25 pack-years) underwent lumpectomy and axillary
dissection (1N+/13) for a 28-mm, grade II, hormone receptor-
positive, HER2-negative, invasive ductal breast carcinoma in 2007.
She subsequently received adjuvant chemotherapy (5-ﬂuorouracil,
epirubicin and cyclophosphamide for three cycles followed by
three cycles of docetaxel), radiotherapy, then anastrozole for
5 years. Seventeen months after the end of anastrozole, metastatic
bone disease was diagnosed. She was prescribed exemestane 25 mg
and everolimus 10 mg daily [2]. At this time, her liver function
tests, cholesterolemia and triglyceridemia were normal. Her co-
medications were zoledronic acid, bromazepam and losartan.
The combination of exemestane and everolimus was well tol-
erated, with grade 2 stomatitis being the worse toxicity. After
1 month of treatment, she developed grade 1 hypercholesterol-
emia (280 mg/dl) and grade 2 hypertriglyceridemia (480 mg/dl),
and was therefore started on fenoﬁbrate 160 mg/day by her
treating physician. Everolimus trough plasma concentration was
10.1 ng/ml (within the range described in the phase I trial at this
dosage [3]) before introduction of fenoﬁbrate. Two weeks later,
stomatitis had regressed, but everolimus trough concentration
le
tte
rs
to
th
e
ed
ito
r
 | letters to the editor Volume 26 | No. 1 | January 2015
letters to the editor Annals of Oncology
